Skip to content
Screener

Supernus Pharmaceuticals SUPN EV / EBITDA

EV / EBITDA at other companies

AbbVie logo
AbbVieABBV
19.8×—
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
40.9×+26.7×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
16.4×-5.2×
XER
Xeris Biopharma Holdings, Inc.XERS
40.5×—
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
7.9×—
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
3.7×+1.2×

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.72B+21.8%
Enterprise value$2.57B+21.5%
P/S3.5×+0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Calculated from Supernus Pharmaceuticals’s reported figures.

enterprise value/ebitda=76.6×

Based on the most recent quarter.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022

FAQ

What is Supernus Pharmaceuticals's EV / EBITDA?
Supernus Pharmaceuticals (SUPN) reported EV / EBITDA of 76.6× in Q1 2026.
How has Supernus Pharmaceuticals's EV / EBITDA changed year-over-year?
Supernus Pharmaceuticals's EV / EBITDA increased by 579.0% year-over-year, from 11.3× to 76.6×.
What is the long-term trend for Supernus Pharmaceuticals's EV / EBITDA?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's EV / EBITDA has grown at a 75.0% compound annual growth rate (CAGR), from 5.8× to 94.3×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Supernus Pharmaceuticals's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude